DelveInsight’s “Vasomotor Symptoms (Hot flashes/Night sweats) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Vasomotor Symptoms market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Vasomotor Symptoms market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Vasomotor Symptoms (Hot flashes/Night sweats) Overview
Vasomotor Symptoms (VMS) manifest as episodes of intense heat accompanied by sweating and flushing, primarily affecting areas like the head, neck, chest, and upper back. These symptoms, often coupled with hot flashes and night sweats, are widely regarded as hallmark signs of menopause. Additionally, VMS may entail heart palpitations and fluctuations in blood pressure.
These symptoms arise due to fluctuations in gonadal hormones, disrupting the body’s temperature regulation mechanisms. Core body temperature (CBT) typically maintains within a specific range, influenced by daily circadian rhythms. Processes involved in heat conservation and dissipation play crucial roles in sustaining optimal internal organ function, necessitating precise regulation of CBT.
The North American Menopause Society (NAMS) advises against treatment until VMS significantly impact a woman’s well-being. The decision to initiate treatment hinges on symptom severity, evaluation of treatment-associated risks, and the individual’s perspectives on menopause and medication. For most women, VMS diminish over time without requiring intervention.
Vasomotor Symptoms (Hot flashes/Night sweats) Market Key Facts
-
In the year 2021, the total prevalent cases of Vasomotor Symptoms were ~136 Million cases in the 7MM, which might decrease by 2032 at a mild CAGR. In the 7MM, the highest number of prevalent cases of Vasomotor Symptoms were observed in the US.
-
In EU4 and the UK, the prevalent cases of Vasomotor Symptoms were ~60 Million cases in the year 2021, which is estimated to decrease by the year 2032 at a mild CAGR. In the EU4 and the UK, the highest number of prevalent cases of Vasomotor Symptoms was observed in Germany.
-
As per the DelveInsight estimates, the total treated cases of Vasomotor Symptoms were highest in the US, followed by Japan, the UK, etc.
-
According to the DelveInsight estimates, the total number of treated cases of Vasomotor Symptoms was 7.47 million cases, respectively, in the 7MM, in the year 2021.
-
According to DelveInsight’s analysis, VMS is most prevalent in females at age 60–65 years old.
Vasomotor Symptoms (Hot flashes/Night sweats) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Vasomotor Symptoms market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Vasomotor Symptoms market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Vasomotor Symptoms (Hot flashes/Night sweats) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Vasomotor symptoms (Hot flashes/Night sweats) Epidemiology, Segmented by –
-
Total Prevalent Cases of Vasomotor Symptoms (VMS) in the 7MM (2019–2032)
-
Total Treated Cases of Vasomotor Symptoms (VMS) in the 7MM (2019–2032)
-
Total Severity-specific Cases of Vasomotor Symptoms (VMS) in the 7MM (2019–2032)
-
Total Age-specific Cases of Vasomotor Symptoms (VMS) in the 7MM (2019–2032)
Vasomotor Symptoms (Hot flashes/Night sweats) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vasomotor Symptoms market or expected to be launched during the study period. The analysis covers the Vasomotor Symptoms market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Vasomotor Symptoms pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Vasomotor Symptoms Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/vasomotor-symptoms-market
Vasomotor Symptoms (Hot flashes/Night sweats) Therapeutics Analysis
The Leading Companies in the Vasomotor symptoms (Hot flashes/Night sweats) Therapeutics Market Include:
-
TherapeuticsMD
-
Mithra Pharmaceuticals (Donesta Biosciences)
-
KaNDy Therapeutics
-
Fervent Pharmaceuticals
-
Astellas Pharma
-
Sojournix
-
Mitsubishi Tanabe Pharma
-
Bayer
-
Nerre Therapeutics Ltd
-
Astellas Pharma
-
MenoGeniX
-
Mitsubishi Tanabe Pharma
-
QUE Oncology
And Many Others
Vasomotor symptoms (Hot flashes/Night sweats) Therapies Covered in the Report Include:
-
Donesta (E4, Estetrol): Estetra/ Mithra Pharmaceuticals
-
Elinzanetant (BAY-3427080, NT 814): Bayer/Nerre Therapeutics Ltd.
-
Fezolinetant (ESN-364): Astellas Pharma
-
MNGX-100(Filgrastim, G-CSF): MenoGeniX
-
Elismetrep (MT-8554): Mitsubishi Tanabe Pharma
-
Q-122 (MSX-122): QUE Oncology
-
MT-8554: Mitsubishi Tanabe Pharma
-
FP-101: Fervent Pharmaceuticals
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/vasomotor-symptoms-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Vasomotor Symptoms Competitive Intelligence Analysis
4. Vasomotor Symptoms Market Overview at a Glance
5. Vasomotor Symptoms Disease Background and Overview
6. Vasomotor Symptoms Patient Journey
7. Vasomotor Symptoms Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Vasomotor Symptoms Treatment Algorithm, Current Treatment, and Medical Practices
9. Vasomotor Symptoms Unmet Needs
10. Key Endpoints of Vasomotor Symptoms Treatment
11. Vasomotor Symptoms Marketed Products
12. Vasomotor Symptoms Emerging Drugs and Latest Therapeutic Advances
13. Vasomotor Symptoms Seven Major Market Analysis
14. Attribute Analysis
15. Vasomotor Symptoms Market Outlook (In US, EU5, and Japan)
16. Vasomotor Symptoms Access and Reimbursement Overview
17. KOL Views on the Vasomotor Symptoms Market
18. Vasomotor Symptoms Market Drivers
19. Vasomotor Symptoms Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/